Bivamelagon: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข1 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions not publicly disclosed. As a small molecule oral tablet, room temperature storage is expected.
Protocol Quick-Reference
Hypothalamic obesity treatment
Dosing
Amount
400-600 mg
Frequency
Once daily
Duration
14 weeks (Phase 2 trial)
Administration
Route
OralTiming
Once-daily oral tablet. Significant practical advantage over setmelanotide, which requires daily subcutaneous injections.
Cycle
Duration
Ongoing (long-term use expected)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (3 tests)
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Baseline liver and kidney function
Fasting glucose and HbA1c
When: Baseline
Why: Baseline metabolic status
Cortisol and pituitary panel
When: Baseline
Why: Assess hypothalamic-pituitary function given target population
๐ก Key Considerations
- โInvestigational drug: not approved by any regulatory authority
- โDeveloped specifically for hypothalamic obesity (rare condition), not general obesity
- โLimited data: Phase 2 trial with 14-week duration in a rare disease population
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Hypothalamic Obesity (Phase 2) | 400 mg or 600 mg once daily oral tablet. | Once daily oral tablet | 14 weeks (Phase 2 trial) | The 600 mg dose achieved 9.3% BMI reduction at 14 weeks. The 400 mg dose achieved 7.7% BMI reduction. Hunger scores decreased by more than 2.8 points at both dose levels. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
No reconstitution required. Bivamelagon is an oral tablet taken once daily.
๐งStorage Requirements
Storage conditions not publicly disclosed. As a small molecule oral tablet, room temperature storage is expected.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Bivamelagon is an investigational drug not approved by any regulatory authority. All dosing information is derived from a Phase 2 clinical trial in hypothalamic obesity.
Phase 2 Trial Dosing#
The Phase 2 trial evaluated two dose levels in patients aged 12 and older with hypothalamic obesity.
| Dose | BMI Reduction at 14 Weeks | Hunger Score Change |
|---|---|---|
| 400 mg daily | -7.7% | Greater than 2.8-point reduction |
| 600 mg daily | -9.3% | Greater than 2.8-point reduction |
Administration#
Bivamelagon is taken as a once-daily oral tablet. This is a significant practical advantage over setmelanotide, which requires daily subcutaneous injections. The oral route is particularly important for the pediatric and adolescent population with hypothalamic obesity.
Target Population#
Bivamelagon is being developed for patients aged 12 and older with hypothalamic obesity, typically resulting from craniopharyngioma treatment (surgery, radiation) or other hypothalamic damage. This is a rare indication with no approved pharmacological treatments.
Dosing Context#
Bivamelagon belongs to the Metabolic category of research peptides. Dosing protocols for Bivamelagon are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Bivamelagon:
Hypothalamic Obesity (Phase 2)#
Dose: 400 mg or 600 mg once daily oral tablet.
Frequency: Once daily oral tablet
Duration: 14 weeks (Phase 2 trial)
The 600 mg dose achieved 9.3% BMI reduction at 14 weeks. The 400 mg dose achieved 7.7% BMI reduction. Hunger scores decreased by more than 2.8 points at both dose levels.
Reconstitution and Preparation#
No reconstitution required. Bivamelagon is an oral tablet taken once daily.
Storage Requirements#
Storage conditions not publicly disclosed. As a small molecule oral tablet, room temperature storage is expected.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Bivamelagon
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.